Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Male and Female Reproductive Disorders
•
Primary Care
Do you regularly counsel younger women of childbearing age about the impact of Tirzepatide on oral hormonal contraception?
https://pubmed.ncbi.nlm.nih.gov/37940101/
Related Questions
What is the typical timeline for remission of autoimmune hypoglycemia?
What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Do you recommend the use of Korlym (Mifepristone) for patients with difficult to control diabetes and evidence of mild endogenous hypercortisolism of unknown source?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
Do you typically adjust pump settings for patients with diabetes who are on automated insulin pumps and fasting all day for religious reasons such as Ramadan?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
When would you treat mild anemia from low testosterone in an older male?
What is the clinical importance of differentiating between impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) states?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?